Align Technology Inc (NASDAQ: ALGN)

$163.61 ▲ +0.54 (+0.33%)

As of May 22, 2026 04:00 PM

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0001097149

Market Cap 11.65 Bn

P/E 27.31

P/S 2.84

Div. Yield 0.00

ROIC (Qtr) 0.00

Revenue Growth (1y) (Qtr) 6.21

Add ratio to table...

About

Align Technology, Inc. is a global medical device company primarily engaged in the design manufacture and marketing of clear aligners for orthodontic treatment intraoral scanners and CAD/CAM software for dental professionals. The company operates in the dental technology industry providing digital solutions that enable orthodontists general practitioners and dental labs to diagnose plan and treat patients. Founded in 1997 and headquartered in Tempe Arizona Align Technology, Inc. has grown to serve customers in over one hundred countries. Its core...

Align Technology, Inc. is a global medical device company primarily engaged in the design manufacture and marketing of clear aligners for orthodontic treatment intraoral scanners and CAD/CAM software for dental professionals. The company operates in the dental technology industry providing digital solutions that enable orthodontists general practitioners and dental labs to diagnose plan and treat patients. Founded in 1997 and headquartered in Tempe Arizona Align Technology, Inc. has grown to serve customers in over one hundred countries. Its core mission is to advance digital orthodontics and restorative dentistry through an integrated platform that connects clinicians labs and patients. The firm continually invests in research and development to expand its product portfolio and improve treatment outcomes.

Align Technology, Inc. generates revenue mainly from the sale of its Invisalign clear aligner system which includes the aligners themselves related accessories and treatment planning software. Additionally the company earns income from the sale of iTero intraoral scanners and associated service contracts as well as from licensing its exocad CAD/CAM software to dental laboratories and clinics. Revenue is derived from direct sales to orthodontists general dental practitioners prosthodontists periodontists oral surgeons and dental laboratories as well as through distributors and sales agents in select international markets. The company also earns revenue from the sale of accessory products such as Vivera retainers whitening kits and cleaning supplies that complement its core aligner offerings. Geographic diversification contributes to its financial stability with sales spread across the Americas Europe and Asia Pacific regions.

The company operates through the following segments: Clear Aligner and Imaging Systems and CAD/CAM Services. These segments are defined by product lines rather than geography and are used internally for resource allocation and performance evaluation.

• Clear Aligner segment focuses on the design manufacture and marketing of Invisalign clear aligners for treating malocclusion along with related products such as Vivera retainers whitening kits and various accessory items that support patient treatment and retention.

• Imaging Systems and CAD/CAM Services segment provides intraoral scanners under the iTero brand and CAD/CAM software through the exocad platform supporting digital imaging treatment planning restorative workflows and digital model fabrication for dental professionals and laboratories.

Align Technology, Inc. holds a leading position in the clear aligner market where it competes with traditional wire and bracket orthodontics as well as emerging clear aligner manufacturers. Its competitive advantages stem from a strong brand reputation a large installed base of over twenty two million treated patients and a proprietary digital platform that integrates scanning treatment planning and manufacturing. The company also benefits from extensive patent protection and a global sales and service network that reinforces its market share against rivals. In addition Align Technology, Inc. invests heavily in education and training programs that increase dentist adoption of its technologies creating a switching cost for practitioners who become familiar with its workflow.

Align Technology, Inc. serves a diverse customer base that includes orthodontists general dental practitioners dental specialists such as prosthodontists periodontists and oral surgeons dental laboratories and dental support organizations that manage multiple practices. The company also sells its products to distributors who in turn supply clinics and hospitals in regions where a direct sales force is not present. While the filing does not disclose specific customer names the company’s products are used by thousands of clinicians and labs across more than one hundred countries contributing to its global brand recognition.

Investment thesis

Bull case

Align’s 2025 results demonstrated that its flagship clear‑aligner business is now a mature, high‑margin revenue engine, with non‑GAAP operating margin hitting 22.7%—the best in more than five years—while gross margin has climbed to 72% on a non‑GAAP basis. The company’s ability to maintain a 4.7% volume lift in a near‑term “soft” macro environment speaks to the resilience of its product pipeline and to the growing digital dentistry ecosystem that has already absorbed significant orthodontic demand. Importantly, the recent surge in systems and services revenue, up 10.3% sequentially driven by iTero Lumina sales, signals a virtuous cycle: higher scanner uptake feeds more Invisalign prescriptions, which in turn boosts aligner volume and margin. These dynamics are expected to accelerate as the company scales manufacturing capacity, reduces cost of goods through direct fabrication, and captures a larger share of the GP and ortho channels worldwide, positioning Align for a disciplined 3%‑4% revenue growth in fiscal 2026 and beyond.
The partnership with Henry Schein One to embed iTero scans directly into Dentrix and Dentally platforms represents a strategic catalyst that Align has kept modest in its public disclosures. By eliminating double‑entry workflows, the integration substantially lowers the operational friction that has historically deterred GP practices from adopting full digital pipelines. In practice, the data shows a measurable lift in scanner utilization rates (86% of full systems units in Q4 2025) and a direct correlation with higher case submission rates—an outcome that can be leveraged to accelerate conversion rates in the U.S. and international markets. The integration also extends to the UK, Ireland, Australia, Canada, and New Zealand, unlocking a global digital ecosystem that positions Align to benefit from the trend toward unified practice management solutions and to outpace competitors that rely on fragmented software stacks.
Direct fabrication, which transitions aligner production from thermal forming to 3‑D printing, is poised to reshape margins once scale is achieved. Though the company acknowledges an initial dilution in 2026 due to higher material and labor costs, the technology offers unparalleled design flexibility and a projected reduction in waste and manufacturing overhead by 2027‑2028. The direct‑fab strategy dovetails with the company’s AI‑enabled ClinCheck platform, enabling more rapid, patient‑specific aligner designs that can be produced on demand, thereby reducing lead times and inventory carrying costs. This convergence of AI, 3‑D printing, and digital workflows is likely to generate incremental revenue streams from high‑value custom attachments (e.g., Invisalign Specifics) and enhance customer lock‑in for both orthodontists and labs.
The company’s expansion into emerging markets—particularly Latin America, APAC (with a strong Chinese presence) and EMEA—has yielded a double‑digit volume uptick in Q4 2025, reflecting the scalability of its digital platform across diverse practice structures. In Mexico and Brazil, for example, Invisalign first–year case starts grew 7.8% year‑over‑year, indicating that early‑intervention products (Invisalign First, Palate Expander, MAOB) are resonating with clinicians and payers alike. The firm’s active rollout of mandibular‑advancement appliances in Thailand and the Philippines further diversifies the product mix, creating new high‑margin revenue streams that are not heavily discounted and which can be cross‑sold to existing customer bases. These market expansions are underpinned by local manufacturing capabilities that reduce exposure to U.S. tariff volatility, giving Align a competitive edge in price‑sensitive environments.
Align’s financial discipline, highlighted by a $1.09 B cash balance and a robust free‑cash‑flow profile of $187 M in Q4 2025, underpins the company’s aggressive capital allocation strategy. The firm’s $1 B stock‑repurchase program, coupled with a high return on equity, suggests that management is focused on delivering shareholder value while preserving liquidity to invest in research and development, manufacturing upgrades, and strategic acquisitions. The non‑GAAP operating margin of 23.7% forecast for 2026 demonstrates the company’s confidence in maintaining leverage even as it expands infrastructure. Moreover, the forecasted 400‑basis‑point improvement in GAAP operating margin relative to 2025 indicates that the company’s cost‑control initiatives—such as accelerated depreciation of disposed assets and restructuring charge optimization—are paying off.

Align’s 2025 results demonstrated that its flagship clear‑aligner business is now a mature, high‑margin revenue engine, with non‑GAAP operating margin hitting 22.7%—the best in more than five years—while gross margin has climbed to 72% on a non‑GAAP basis. The company’s ability to maintain a 4.7% volume lift in a near‑term “soft” macro environment speaks to the resilience of its product pipeline and to the growing digital dentistry ecosystem that has already absorbed significant orthodontic demand. Importantly, the recent surge in systems and services revenue, up 10.3% sequentially driven by iTero Lumina sales, signals a virtuous cycle: higher scanner uptake feeds more Invisalign prescriptions, which in turn boosts aligner volume and margin. These dynamics are expected to accelerate as the company scales manufacturing capacity, reduces cost of goods through direct fabrication, and captures a larger share of the GP and ortho channels worldwide, positioning Align for a disciplined 3%‑4% revenue growth in fiscal 2026 and beyond.
The partnership with Henry Schein One to embed iTero scans directly into Dentrix and Dentally platforms represents a strategic catalyst that Align has kept modest in its public disclosures. By eliminating double‑entry workflows, the integration substantially lowers the operational friction that has historically deterred GP practices from adopting full digital pipelines. In practice, the data shows a measurable lift in scanner utilization rates (86% of full systems units in Q4 2025) and a direct correlation with higher case submission rates—an outcome that can be leveraged to accelerate conversion rates in the U.S. and international markets. The integration also extends to the UK, Ireland, Australia, Canada, and New Zealand, unlocking a global digital ecosystem that positions Align to benefit from the trend toward unified practice management solutions and to outpace competitors that rely on fragmented software stacks.
Direct fabrication, which transitions aligner production from thermal forming to 3‑D printing, is poised to reshape margins once scale is achieved. Though the company acknowledges an initial dilution in 2026 due to higher material and labor costs, the technology offers unparalleled design flexibility and a projected reduction in waste and manufacturing overhead by 2027‑2028. The direct‑fab strategy dovetails with the company’s AI‑enabled ClinCheck platform, enabling more rapid, patient‑specific aligner designs that can be produced on demand, thereby reducing lead times and inventory carrying costs. This convergence of AI, 3‑D printing, and digital workflows is likely to generate incremental revenue streams from high‑value custom attachments (e.g., Invisalign Specifics) and enhance customer lock‑in for both orthodontists and labs.
The company’s expansion into emerging markets—particularly Latin America, APAC (with a strong Chinese presence) and EMEA—has yielded a double‑digit volume uptick in Q4 2025, reflecting the scalability of its digital platform across diverse practice structures. In Mexico and Brazil, for example, Invisalign first–year case starts grew 7.8% year‑over‑year, indicating that early‑intervention products (Invisalign First, Palate Expander, MAOB) are resonating with clinicians and payers alike. The firm’s active rollout of mandibular‑advancement appliances in Thailand and the Philippines further diversifies the product mix, creating new high‑margin revenue streams that are not heavily discounted and which can be cross‑sold to existing customer bases. These market expansions are underpinned by local manufacturing capabilities that reduce exposure to U.S. tariff volatility, giving Align a competitive edge in price‑sensitive environments.
Align’s financial discipline, highlighted by a $1.09 B cash balance and a robust free‑cash‑flow profile of $187 M in Q4 2025, underpins the company’s aggressive capital allocation strategy. The firm’s $1 B stock‑repurchase program, coupled with a high return on equity, suggests that management is focused on delivering shareholder value while preserving liquidity to invest in research and development, manufacturing upgrades, and strategic acquisitions. The non‑GAAP operating margin of 23.7% forecast for 2026 demonstrates the company’s confidence in maintaining leverage even as it expands infrastructure. Moreover, the forecasted 400‑basis‑point improvement in GAAP operating margin relative to 2025 indicates that the company’s cost‑control initiatives—such as accelerated depreciation of disposed assets and restructuring charge optimization—are paying off.

Bear case

Align’s dependence on DSOs for a significant portion of its revenue—approximately 25% of clear‑aligner volume—poses a concentration risk that could materialize if the DSOs face staffing shortages, profitability pressures, or a shift toward in‑house technology solutions. The company has disclosed that DSOs are a “high‑growth, digitally‑forward” channel, yet DSOs’ reliance on third‑party vendors for scanners and software (e.g., iTero, Exocad) introduces an ecosystem risk: any disruption in partner relationships could reduce scanner utilization and, by extension, aligner case submissions. Moreover, DSOs’ subscription‑based models may become vulnerable if dentists begin to consolidate further or shift toward hybrid practice models, thereby diluting the incentive for early‑stage adoption of Invisalign products.
The direct fabrication rollout, while potentially margin‑positive in the long term, is currently dilutive and could strain cash flow if scaling is slower than anticipated. The company’s own guidance indicates that the first production year will involve a net margin hit before the 2027–2028 upside materializes. If the projected ramp‑up takes longer due to supply‑chain constraints or technical challenges, Align could face additional capital expenditures without commensurate revenue growth, undermining the forecasted 400‑basis‑point improvement in GAAP operating margin for 2026.
Foreign‑exchange headwinds have already manifested in a downward pressure on revenue and margins: the company reported a $3 M adverse FX impact in Q4 2025, a $14 M positive FX impact year‑over‑year, and a $2.5 M favorable FX impact on systems and services. These fluctuations expose the company to currency risk, particularly as it expands into China and other emerging markets where local currency volatility can erode pricing power. Additionally, the ongoing VBP implementation in China presents an uncertain pricing environment that could erode the company’s ASP and lead to lower volumes if dental providers shift toward more cost‑effective alternatives under a VBP framework.
Despite robust Q4 growth, the company’s year‑over‑year revenue increase for 2025 was only 0.9%, and the forecast for fiscal 2026 caps growth at 3%‑4%. These modest upside expectations may be overly conservative given the potential for a broader recovery in the dental market, but they also signal a cautious stance that could under‑capture the upside. A sluggish macro environment, with consumer discretionary spending remaining subdued, may dampen the projected mid‑single‑digit volume growth and keep the ASP below 2025 levels, thereby eroding the operating margin improvements management touts.
Management’s Q&A revealed a certain level of evasiveness regarding discounting strategies and pricing mix: while the company highlighted a favorable mix shift to higher‑priced markets, it also acknowledged “higher discounts” and “higher net deferrals” as key factors that partially offset volume gains. The continued discounting—particularly in North America, where the market remains soft—could erode the gross margin, especially as the company’s cost of goods remains high for early‑stage products like Invisalign First. If discounting intensifies to maintain volume, the margin compression could become a persistent risk that outweighs volume gains.

Align’s dependence on DSOs for a significant portion of its revenue—approximately 25% of clear‑aligner volume—poses a concentration risk that could materialize if the DSOs face staffing shortages, profitability pressures, or a shift toward in‑house technology solutions. The company has disclosed that DSOs are a “high‑growth, digitally‑forward” channel, yet DSOs’ reliance on third‑party vendors for scanners and software (e.g., iTero, Exocad) introduces an ecosystem risk: any disruption in partner relationships could reduce scanner utilization and, by extension, aligner case submissions. Moreover, DSOs’ subscription‑based models may become vulnerable if dentists begin to consolidate further or shift toward hybrid practice models, thereby diluting the incentive for early‑stage adoption of Invisalign products.
The direct fabrication rollout, while potentially margin‑positive in the long term, is currently dilutive and could strain cash flow if scaling is slower than anticipated. The company’s own guidance indicates that the first production year will involve a net margin hit before the 2027–2028 upside materializes. If the projected ramp‑up takes longer due to supply‑chain constraints or technical challenges, Align could face additional capital expenditures without commensurate revenue growth, undermining the forecasted 400‑basis‑point improvement in GAAP operating margin for 2026.
Foreign‑exchange headwinds have already manifested in a downward pressure on revenue and margins: the company reported a $3 M adverse FX impact in Q4 2025, a $14 M positive FX impact year‑over‑year, and a $2.5 M favorable FX impact on systems and services. These fluctuations expose the company to currency risk, particularly as it expands into China and other emerging markets where local currency volatility can erode pricing power. Additionally, the ongoing VBP implementation in China presents an uncertain pricing environment that could erode the company’s ASP and lead to lower volumes if dental providers shift toward more cost‑effective alternatives under a VBP framework.
Despite robust Q4 growth, the company’s year‑over‑year revenue increase for 2025 was only 0.9%, and the forecast for fiscal 2026 caps growth at 3%‑4%. These modest upside expectations may be overly conservative given the potential for a broader recovery in the dental market, but they also signal a cautious stance that could under‑capture the upside. A sluggish macro environment, with consumer discretionary spending remaining subdued, may dampen the projected mid‑single‑digit volume growth and keep the ASP below 2025 levels, thereby eroding the operating margin improvements management touts.
Management’s Q&A revealed a certain level of evasiveness regarding discounting strategies and pricing mix: while the company highlighted a favorable mix shift to higher‑priced markets, it also acknowledged “higher discounts” and “higher net deferrals” as key factors that partially offset volume gains. The continued discounting—particularly in North America, where the market remains soft—could erode the gross margin, especially as the company’s cost of goods remains high for early‑stage products like Invisalign First. If discounting intensifies to maintain volume, the margin compression could become a persistent risk that outweighs volume gains.

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ISRG	Intuitive Surgical Inc	156.17 Bn	52.64	14.76	-
2	BDX	Becton Dickinson & Co	41.51 Bn	29.74	1.94	17.28 Bn
3	RMD	Resmed Inc	30.43 Bn	20.13	5.50	0.26 Bn
4	WST	West Pharmaceutical Services Inc	22.78 Bn	42.07	7.07	0.20 Bn
5	SOLV	Solventum Corp	13.39 Bn	9.37	1.62	5.08 Bn
6	COO	Cooper Companies, Inc.	12.33 Bn	31.01	2.97	2.50 Bn
7	ALGN	Align Technology Inc	11.65 Bn	27.31	2.84	-
8	BAX	Baxter International Inc	9.81 Bn	-72.70	0.91	9.46 Bn

Research Tools

Developers

Align Technology Inc (NASDAQ: ALGN)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

Align Technology Inc (NASDAQ: ALGN)

About

Investment thesis

Bull case

Bear case

Segments Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password